Mounjaro and Liver Disease — What Australian Patients Need to Know

Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist made by Eli Lilly. It was TGA-approved in Australia in September 2024 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Unlike semaglutide (Ozempic and Wegovy), which activates only the GLP-1 receptor, tirzepatide activates two receptors simultaneously — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is one reason why Mounjaro produces greater average weight loss than semaglutide in head-to-head comparisons — approximately 20–21% body weight reduction on average, compared to 14–17% for semaglutide.

For liver health, the dual mechanism is also potentially significant. Both GLP-1 and GIP receptors are expressed in liver tissue, and preclinical and early clinical data suggest tirzepatide may have additive hepatic benefits compared to GLP-1 alone.

The evidence base for tirzepatide and liver disease is not yet as extensive as that for semaglutide, but the signals are consistently positive.

Phase 2 clinical trials have shown that tirzepatide produces significant reductions in liver fat content, liver enzyme levels, and markers of liver inflammation in patients with MASLD and type 2 diabetes.

The SYNERGY-NASH trial — a dedicated phase 3 trial of tirzepatide in patients with MASH — completed enrolment in 2025, with results expected in 2026. If the results replicate or exceed the semaglutide data from ESSENCE, tirzepatide is likely to become the second GLP-1 medication to receive regulatory approval for treating MASH.

Meanwhile, given the magnitude of weight loss tirzepatide produces, significant liver fat reduction is expected as a secondary benefit in most patients — MASLD is closely linked to obesity, and a 20% reduction in body weight produces substantial improvement in liver histology.

The liver benefits of GLP-1 receptor agonists are well-established: reduced fat delivery to liver cells, improved insulin sensitivity, reduction in liver inflammation, and direct effects on fibrosis pathways via GLP-1 receptors expressed on liver sinusoidal endothelial cells.

GIP receptor activation adds additional metabolic effects that may complement the liver benefits of GLP-1 — including improved lipid metabolism, reduced visceral adiposity, and potentially direct GIP receptor-mediated effects on liver fat metabolism.

The combination means Mounjaro addresses fatty liver disease through more pathways simultaneously than Ozempic or Wegovy, and the early clinical data suggests this translates to greater liver fat reduction — though head-to-head liver histology data comparing tirzepatide directly to semaglutide in MASH patients is still emerging.

Based on current clinical data, Mounjaro does not appear to cause liver damage. Phase 2 and 3 trial safety data consistently shows a favourable hepatic safety profile, with no clinically significant drug-induced liver injury identified.

The same caveat that applies to semaglutide applies here: rapid weight loss — which occurs to a greater degree on Mounjaro than on any other approved weight management medication — can temporarily elevate liver enzymes as the liver processes mobilised fat stores. This is a consequence of the rate of fat mobilisation rather than any toxic effect of the drug on liver cells.

In the context of pre-existing MASLD, elevated enzymes on Mounjaro may actually reflect pre-existing disease being unmasked by routine testing, rather than new drug-induced injury. Baseline liver function testing before starting Mounjaro is the most effective way to distinguish between these possibilities.

The monitoring approach for Mounjaro mirrors that recommended for semaglutide in Australian guidelines. Before starting Mounjaro, a standard liver function panel including ALT, AST, GGT, alkaline phosphatase, bilirubin, and platelets allows a FIB-4 score to be calculated.

A FIB-4 below 1.3 indicates low risk of advanced fibrosis — monitor annually.

A FIB-4 between 1.3 and 2.67 is indeterminate — liver elastography recommended.

A FIB-4 above 2.67 indicates high risk — referral to a hepatologist or gastroenterologist.

During Mounjaro therapy, a repeat liver function panel at 3 months assesses for any transient enzyme changes during the early rapid weight loss phase. At 12 months, repeat FIB-4 calculation can assess whether liver function has improved in line with weight loss.

This question is at the frontier of current clinical research. The SYNERGY-NASH trial will provide the most definitive answer to date. Based on existing data and the known mechanisms, the expected trajectory is:

In the first 3 months: liver fat content decreases significantly as weight reduces. Liver enzymes may transiently fluctuate during rapid weight loss, then stabilise.

At 6–12 months: sustained liver fat reduction. In patients with MASLD, liver stiffness measurements (elastography) may begin to improve as inflammation resolves. Liver enzyme levels typically normalise or significantly improve.

At 12–24 months: patients with MASH (significant inflammation and early fibrosis) may see histological improvement in fibrosis stage — though the magnitude of this effect with tirzepatide is yet to be fully characterised in completed phase 3 data.

The same considerations that apply to Ozempic and Wegovy apply here. Consider discussing liver elastography with your GP if:

• You have type 2 diabetes, obesity, or metabolic syndrome
• You have had any elevated liver enzymes on a blood test, at any point in the past or since starting Mounjaro
• Your FIB-4 score is in the indeterminate range (1.3–2.67)
• You have a family history of liver disease
• You drink alcohol regularly
• You are losing weight rapidly (more than 1.5kg per week) on Mounjaro

A liver elastography scan is non-invasive, takes 10–15 minutes, and provides a definitive picture of whether significant liver fibrosis is present. It is available at clinics across Australia, and a growing number accept self-referred patients without a GP referral.

Find a liver elastography clinic near you →

This is one of the most common questions from patients comparing the two medications. The honest answer is that we do not yet have definitive head-to-head liver histology data.

What we know: semaglutide (Ozempic/Wegovy) has phase 3 MASH trial data (ESSENCE) demonstrating 62.9% MASH resolution and TGA approval for MASH. Tirzepatide (Mounjaro) has phase 2 liver data and a completed phase 3 enrolment (SYNERGY-NASH) with results pending.

What the data suggests: tirzepatide produces greater weight loss on average than semaglutide, and weight loss is closely correlated with liver fat reduction. The dual GLP-1/GIP mechanism may add liver benefits beyond weight loss. If the SYNERGY-NASH results replicate or exceed the ESSENCE data, Mounjaro may emerge as the more potent liver treatment — but this is speculative until the data is available.

For patients who already have significant MASH with fibrosis and need treatment now, Wegovy is the only option with current TGA approval specifically for MASH. For patients managing weight with comorbid fatty liver disease and willing to wait for emerging data, Mounjaro may emerge as a preferred option.